Avacta reaches milestone in AVA6000 dose escalation
21st Mar 2024 13:10
(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.
Read moreAvacta tumbles after raising £25.7m in heavily discounted placing
29th Feb 2024 08:27
(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.
Read moreAvacta appoints new head of research and development
19th Jan 2024 11:18
(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.
Read moreAvacta appoints new chief business officer
19th Dec 2023 10:24
(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.
Read moreAvacta hails "encouraging" clinical data from cancer-targeting study
13th Dec 2023 07:46
(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".
Read moreAvacta reports higher losses in first half
28th Sep 2023 07:57
(Sharecast News) - Cancer treatments and diagnostics group Avacta reported higher losses in the first half despite a doubling of revenues.
Read moreAvacta brings in clinical consultant as it hunts for permanent CMO
20th Sep 2023 11:57
(Sharecast News) - Oncology-focussed life science company Avacta Group announced a new consultancy pact with Dr Christina Coughlin on Tuesday.
Read moreAvacta upbeat on fresh data from chemotherapy trial
19th Sep 2023 13:39
(Sharecast News) - Life sciences company Avacta Group announced the successful completion of its sixth dose escalation cohort in the ALS-6000-101 phase one clinical trial on Tuesday, assessing the safety and tolerability of the drug, AVA6000.
Read moreAvacta completes fifth dose escalation in chemotherapy trial
21st Jun 2023 13:53
(Sharecast News) - Life sciences company Avacta announced the successful completion of the fifth dose escalation cohort in the phase 1 clinical trial for AVA6000 on Wednesday.
Read moreAvacta denies press speculation over potential fundraising
19th Jun 2023 10:16
(Sharecast News) - Oncology drug developer Avacta Group responded to recent market speculation over a potential fundraising initiative on Monday.
Read moreAvacta triggers second milestone payment in AffyXell venture
5th Jun 2023 12:28
(Sharecast News) - Life science company Avacta Group announced on Monday that a second milestone equity payment had been triggered, resulting in an increased shareholding for Avacta in AffyXell Therapeutics.
Read moreAvacta buys Belgium-based Coris Bioconcept for £7.4m
1st Jun 2023 14:53
(Sharecast News) - Life science company Avacta Group announced the acquisition of Coris Bioconcept for initial cash consideration of £7.4m on Thursday.
Read moreAvacta doses first patient in US tumour treatment trial
27th Apr 2023 12:11
(Sharecast News) - Oncology and diagnostics developer Avacta announced the dosing of the first patient in the United States under its investigational new drug (IND) application on Thursday - a milestone for its first therapeutic product 'AVA6000', based on its proprietary 'preCISION' technology.
Read moreRevenue rises, adjusted EBITDA loss improves for Avacta
25th Apr 2023 13:51
(Sharecast News) - Oncology-focussed drugs and diagnostics developer Avacta reported full-year revenue of £9.7m in its preliminary results on Tuesday, up from £2.9m year-on-year.
Read moreAvacta presents pre-clinical data for anti-cancer candidate
17th Apr 2023 09:43
(Sharecast News) - Life science company Avacta Group announced the presentation of pre-clinical data for its novel 'preCISION' proteasome inhibitor AVA3996 on Monday.
Read more